No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot gene edit­ing field

When Affi­ni-T ar­rived on the scene a few weeks ago, it had most of the es­sen­tial el­e­ments need­ed by any biotech up­start.

There were high-pro­file sci­en­tif­ic founders, Phil Green­berg, Tom Schmitt and Aude Cha­puis, at the Fred Hutch. A moth­er­lode of cash from am­bi­tious in­vestors like Vi­da Ven­tures and Leaps by Bay­er. And the build­ing blocks of new drugs to go af­ter onco­genic dri­vers like KRAS and p53.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER